RxDoctor Payments Data

John Dickson, MD

Internal Medicine · San Antonio, TXNPI 1154467116

Payments from drug & device makers

$7,545in general payments, 2019–2025

Across 360 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$921
  • AbbVie$594
  • AstraZeneca$529
  • Lilly USA, LLC$515
  • Johnson & Johnson$446
  • Abbott$411
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$7,532100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,545 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$180,868
Medicare patients
487
Services billed
2,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide167$211,856
JardianceEmpagliflozin138$175,351
EliquisApixaban116$132,414
TrulicityDulaglutide32$41,414
FarxigaDapagliflozin Propanediol21$32,636
JanuviaSitagliptin Phosphate17$23,781
MyrbetriqMirabegron23$18,778
XareltoRivaroxaban12$18,542
Bydureon BciseExenatide Microspheres13$12,527
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen138$6,922
Rosuvastatin Calcium539$6,377
Omeprazole311$6,329
Dexlansoprazole DrDexlansoprazole15$5,953
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,631
Humalog Kwikpen U-100Insulin Lispro14$5,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$246$211,856167 claims
Boehringer IngelheimJardiance$347$175,351138 claims
PfizerEliquis$118$132,414116 claims
Lilly USA, LLCTrulicity$515$41,41432 claims
AstraZenecaFarxiga, Symbicort$529$35,33233 claims
Johnson & JohnsonXarelto$446$18,54212 claims
GSKAnoro Ellipta$395$5,24211 claims
AbbVieSynthroid$594$2,84333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →